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Abstract
Cancer therapy is largely dependent on general treatment
guidelines, and patients undergoing chemotherapy often
experience treatment failure with standard drugs. The
development of individualized drug therapy through pharmacogenomics has the potential to enhance chemotherapy
regimen selection and improve patient outcomes. Antineoplastic agents such as cetuximab and trastuzumab are effective in treating cancers possessing specific genetic biomarker
characteristics. Patients need to undergo genetic testing
before these agents are administered to ensure appropriate
use. Cetuximab has been shown to improve outcomes in
metastatic colorectal cancers and head and neck squamous
cell carcinomas positive for EGFR. Trastuzumab has shown
benefit in human epidermal growth factor receptor 2 (HERZ)
overexpressing cancers affecting the breast tissue and
gastrointestinal tract. High costs associated with the development of targeted drugs and a lack of clinical studies
exploring the effects genetic variations can have on drug
therapy limit implementation of pharmacogenomics into
routine practice. As drug therapy experts, pharmacists need
to be aware of advances in the field of pharmacogenomics
and facilitate the use of this new class of personalized drugs.

Introduction
Patients diagnosed with cancer are treated on the basis of
standard drug therapy and dosing guidelines. 1 Many factors,
such as body weight, age and medical history, may also be
considered in choosing a medication regimen. Despite these
considerations, a patient's response to drug therapy cannot
be predicted using current methods and practice guidelines.
This could translate into repeat visits to the oncologist for
medication changes and additional rounds of chemotherapy,
with an increased risk of incapacitating side effects. For
patients diagnosed with cancer, therapeutic failure can be
devastating and there is often little time for a trial and error
approach. The development of individualized therapy
through pharmacogenomics has the potential to enhance
chemotherapy regimen selection and improve patient
outcomes. Targeted antineoplastic medications, such as
cetuximab and trastuzumab, can be extremely beneficial in
oncology patients with specific genetic variant biomarkers,
but also have the potential to cause life-threatening adverse
effects. In order to reduce patients' exposure to dangerous
medications in the absence of a potential benefit, genetic
testing is required prior to administration of these drugs to
identify those patients who will most likely exhibit a positive
response. Despite the obvious benefits of pharmacogenomics, barriers exist in both research and integration into
practice. Pharmacists are in a key position to advocate for
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individualized drug therapy and to inform other health care
providers on the use and benefits of pharmacogenomics.

Figure 1. Average chemotherapeutic drug failure.z
PERCENTAGE OF THE PATIENT POPULATION FOR WHICH
A PARTICULAR DRUG IS INEFFECTIVE, ON AVERAGE

CANCER DRUGS

75%

Cetuximab
Cetuximab (Erbitux®) is a recombinant chimeric IgG 1 antibody that binds to the extracellular domain of epidermal
growth factor receptor (EGFR)-1. EGFR is responsible for the
growth and differentiation of epithelial cells. When epidermal growth factor (EGF) binds to the extracellular domain of
EGFR, receptor dimerization occurs and intracellular protein
tyrosine kinases are activated. Following kinase activation,
various signaling pathways are stimulated, such as RAS-RAFmitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K-AKT) pathways. Once activated, these
pathways' signals can regulate cell proliferation, differentiation and survival. Cetuximab binds to the extracellular
domain of EGFR with high affinity and competitively inhibits
ligands from binding to the receptor.3 This leads to inhibition
of phosphorylation of intracellular protein tyrosine kinases
and prevents the activation of the downstream signaling
pathways, resulting in the inhibition of cell growth and proliferation, ultimately inhibiting tumor growth (Figure 2).
Cetuximab was the first EGFR inhibitor approved for the
treatment of metastatic colorectal cancer (mCRC). It is used
as monotherapy in the treatment of EGFR-positive mCRC in
patients who cannot tolerate traditional irinotecan-based
therapy or in combination with irinotecan in patients who
did not respond to oxaliplatin, irinotecan and 5-fluorouracil
(5-FU). Traditional therapy in the treatment of mCRC includes a combination of 5-FU or capecitabine, with either
oxaliplatin or irinotecan. Using cetuximab in combination
with 5-FU and irinotecan or oxaliplatin has been shown to
improve outcomes in the first- and second-line setting of
mCRC.
Cetuximab can improve overall survival when used in combination with radiation therapy in the treatment of locally or
regionally advanced head and neck squamous cell carcinoma
(HNSCC). It is used as a monotherapy agent in patients with
metastatic or recurrent HNSCC. These patients do not typically respond to platinum-based chemotherapy. Cetuximab
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A randomized trial completed by the National Cancer Institute of Canada Clinical Trials Group with the Australasian
Gastro-Intestinal Trials Group demonstrated that patients
harboring KRAS mutations had reduced response rates to
cetuximab therapy, compared to patients with wild-type
KRAS genes. The cetuximab therapy group revealed that patients with wild-type KRAS tumors had a response rate to
cetuximab that was 12.8 percent, compared to a 1.2 percent
response rate in patients with a mutated KRAS gene.6
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has also been shown to improve survival when used in combination with cisplatin-based chemotherapy, as compared to
cisplatin alone. 4
KRAS Mutation
RAS proteins are involved in the EGFR signaling pathways
that ultimately result in cell proliferation, differentiation and
survival. The three human RAS genes-HRAS, KRAS and
NRAS -- are involved in the pathogenesis of tumors through
cell proliferation, angiogenesis and anti-apoptosis pathways.3
RAS proteins are small GTP-GDP-binding proteins which act
as self-inactivating signal transducers cycling from the GDPto GTP-bound states as a result of EGF binding to the EGFR.
These oncogenic RAS proteins have reduced GTPase activity
which results in an abundance of RAS proteins in the GTPbound active state due to an inability to cycle back to the GDP
-bound inactive state. This results in further activation of the
downstream signaling pathways promoting cancer cell
proliferation, angiogenesis and resistance to apoptosis.
Mutations in the coding region of the KRAS gene lead to a
constitutively active gene, which is not dependent on
upstream activation of the EGFR. Cetuximab prevents the
downstream cell signaling pathways from occurring by
blocking EGF from binding the EGFR. Because EGFR activation results in KRAS protein activation, mutations in the coding region of the KRAS gene lead to a constitutively active
KRAS gene. This mutated KRAS gene is not dependent on the
upstream signaling pathways.s
Figure 2: Cetuximab and its effects on the EGF pathway. 3
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Mutations of the KRAS gene occur as point mutations in
codons 12 and 13 of exon 2. These mutations occur early in
the development of mCRC carcinogenesis. Thirty-five to 40
percent of colorectal cancer (CRC) cases have KRAS mutations. KRAS mutation incidence is identical among all stages
of CRC. Identification of KRAS mutations are considered to be
a predictor of testing resistance to anti-EGFR monoclonal
antibody therapy.3 The American Society of Clinical Oncology
Provisional Clinical Option has issued a recommendation
that all patients with mCRC that are candidates for anti-EGFR
monoclonal antibody therapy must have tumor cells tested
for the presence of KRAS mutations prior to initiating drug
therapy.7 If the results show a KRAS mutation in codons 12
or 13, patients should not receive anti-EGFR monoclonal antibody therapy due to predicted resistance.
Testing for KRAS Mutations
KRAS mutations are detected by the DxS-K-ras test kit. It can
detect seven somatic mutations on codons 12 and 13 on the
KRAS gene. The kit has seven primers that are specific in detecting the most common mutations in codons 12 and 13.
These primers are complementary to the KRAS gene immediately adjacent to the mutation sites. Each primer has a
unique sequence at the 3' end specific for the mutation. During polymerase chain reaction (PCR) amplification, the primers attach to the template strand and only the primer with
the complementary nucleotide at the 3' end will extend the
mutated target DNA.S Taq DNA polymerase is used in this
test because it is very effective in distinguishing the differences between a match and mismatch nucleotide at the 3'
end of a PCR primer. If the primer completely matches, amplification will occur with full efficiency; in the case of a 3'
nucleotide base pair mismatch, amplification is reduced. This
means only the mutated strand that matches the primer will
be able to be extended. Amplification is detected using Scorpions, which are bifunctional molecules with a PCR primer
covalently linked to a fluorescent probe. The fluorophore in
the probe reacts with a quencher in the probe which results
in a reduction in fluorescence. During the PCR amplification
the probe binds to an amplicon, causing the fluorephore and
quencher in the probe to become separated and increasing
the amount of fluorescence observed in the reaction tube.
Mutated KRAS genes will demonstrate a greater fluorescence
reaction than wild-type KRAS genes because the mutated
genes have a greater amount of amplification during PCR
than the wild-type KRAS gene.a
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Alternative Treatment Options for Patients with KRAS Trastuzumab is only efficacious in HER2 overexpressing canMutations
cers, which is why genetic testing must be performed before
The KRAS oncogene is the most commonly mutated gene in it can be prescribed. The most recent indication for this
different human cancers and, due to its constitutive activity, medication is in esophageal adenocarcinoma (EAC). Two
it has the ability to bypass EGFR signaling cascade, therefore different EAC cell lines, OEl 9 and OE33, both overexpress
conferring resistance to anti-EGFR therapies such as cetuxi- HER2. Researchers compared trastuzumab efficacy in these
mab. Since patients with mCRC harboring KRAS mutations do cell lines and a non-HER2 overexpressing cell line. Both the
not show a clinical response to cetuximab, they will have to
OEl 9 and OE33 cell lines had inhibited proliferation when
consider other treatment options in order to control and treated with trastuzumab, while the non-HER2 overexpresstreat their cancer. Some of these options include therapy that ing cell line had no alteration in cellular growth when treated
targets molecules downstream of RAS proteins such as RAF with trastuzumab. Levels of interferon-y (INF-y) produced by
inhibitors. RAF is an effector molecule downstream of RAS in the OE33 cell line were significantly greater when treated
the ERK signaling pathway, making it a potential target for with trastuzumab resulting in an increased cytotoxicity to
treating KRAS mutated tumors. Sorafenib, one of the first the cell line. The OEl 9 cell line did not initially have the
RAF inhibitors, has multikinase inhibitory actions against increased cytotoxicity associated with trastuzumab adminiCRAF, BRAF, V600E mutant form of BRAF, vascular endothe- stration, owing to a deficiency of the TAP-2 protein, an antilial growth factor receptor (VEGFR) and platelet derived gen peptide transporter. The TAP-2 protein is required for
growth-factor receptor (PDGFR). Sorafenib has been ap- proper antigen processing by the MHC-class 1 molecules.
proved for the treatment of advanced renal cell carcinoma However, when treated with INF-y, an upregulator for the
and hepatocellular carcinoma; however it is a relatively weak TAP-2 protein and then treated with trastuzumab, the OEl 9
RAF inhibitor. Another option is using a combination of tar- cell line was also sensitized to cytotoxicity by CTLs through a
geted agents. Since RAS activation results in activation of MHC-class 1 mediated process.11
various branching pathways, blocking one downstream target of RAS will theoretically not be enough to inhibit tumor The HER2 proto-oncogene is found on the long arm of
growth. Dual-targeted or multi-targeted therapy may be chromosome 17. Determination of HER2 protein and gene
more efficient in eliminating cancer cells and fighting drug overexpression is performed through immunohistochemisty
resistance in those patients with KRAS mutations.3
(IHC) and in situ hybridization, either fluorescence (FISH) or
chromogenic (CISH), respectively. 12 IHC determines a posiTrastuzumab
tive or negative result for HER2 overexpression through the
Trastuzumab (Herceptin®) is a human epidermal growth percentage of membrane staining that occurs; if over 30 perfactor receptor 2 (HER2) antagonist. It is indicated as a treat- cent of the cells in the sample have complete membrane
ment option in HER2 overexpressing cancers such as breast staining, a +3 or positive score is assigned.13 A FISH result is
cancer in combination with doxorubicin, cyclophosphamide determined by the ratio of the number HER2 signals to the
and paclitaxel or docetaxel; metastatic breast cancer as an number of chromosome 17 signals; the result is considered
adjuvant treatment with paclitaxel or used alone; and metas- positive for HER2 overexpression if the ratio is greater than
tatic gastric or gastroesophageal junction adenocarcinoma in 6 to 1.13 However, the American Society of Clinical Oncology
conjunction with cisplatin, capecitabine or 5-FU.9
(ASCO) reports that approximately 20 percent of all testing
may be inaccurate.
Epidermal growth factor receptors (HER) dimerize upon
ligand binding, thereby activating the receptor's tyrosine The limitations to determining HERZ overexpression in cankinase activity. There are four types of HER proteins: HER1, cer are due to a variety of factors. The IHC scoring interpretaHER2, HER3 and HER4. HER2 has no endogenous epidermal tion can be highly variable among different laboratories. In
growth factor ligand, but has been determined to be the most order to minimize this subjectivity, recent studies have used
preferential binding partner for dimerization with HERl, both IHC and FISH to properly determine HER2 expression.
HER3 and HER4 and therefore acts primarily as a co- In a 2011 study all +3 IHC results also had HER2 amplificareceptor.10 These heterodimeric receptors have altered phos- tion.12 The limitation of the FISH ratio is due to the potential
phorylation sites and cause modified activity. The HER2 het- of chromosome 17 variations in the centromere. The centroerodimers decrease the internalization of the receptor mere can exhibit polysomy, having too many copies of the
thereby amplifying and diversifying the altered signaling centromere or monosomy, having only one copy of the cenpathways. These signals ultimately lead to the formation of tromere and these alterations are thought to contribute to
cancer through increased cellular proliferation and, poten- the inaccuracy of testing. 14 This study demonstrated that
tially, metastasis of these cancers by increasing the cellular artificial skewing due to an altered centromere caused false
migration. It has been observed that HER2 is immunogenic, positive or false negative results. In the case of monosomy,
as many cancer patients express cytotoxic T-lymphocytes positive results should be considered with caution as the
(CTL) which target HER2. 11 Trastuzumab inhibits this cellu- decreased centromere number can produce an overexaggerlar proliferation and migration by binding to HER2 and in- ated HER2/CEP17 ratio. In cases of polysomy, negative reducing antibody dependent cellular cytotoxicity (ADCC). It sults should be closely examined as a lower than expected
also causes an upregulation of the MHC-class 1 receptors ratio may occur if the CEPl 7 has many more than two cencontaining the HER2 epitope in overexpressing cancer cells.11 tromeres.14 These factors must therefore be taken into careful consideration when conducting the mandatory genetic
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testing prior to prescribing trastuzumab.
Motivations and Liinitations to Pharmacogenoinic Drug
Development
Although pharmacogenetic testing has not become commonplace in all pharmaceutical settings, it is becoming increasingly prevalent before prescribing and to determine dosing
for many oncology treatments. Many different types of cancer can now be identified based upon the specific genetic
factors present. Cancer treatments are now being tailored to
target these specific mutations, allowing these treatments to
be more specific and efficacious. All chemotherapeutics have
the potential for life-threatening adverse effects and should
therefore not be prescribed unless the potential benefits outweigh the risks, a determination which cannot be conclusively made for some drugs without the use of genetic testing.
The limitation to this testing and development of genetically
targeted drugs lies within the fact that the current costs to
develop these medications do not cover the potential financial gains from these developments. Although the financial
gains may not meet the costs of development, the quality of
life (QOL) improvements gained by patients from these
medications justify continued research. A 2008 study in Sweden demonstrated that the costs of FISH testing and concurrent treatment with trastuzumab for positive results (cost
approximately $63,000) provided a gain of almost 1.5 quality
adjusted life years (QAL Y). The average costs of these treatments were below the typical willingness to pay threshold
and therefore this treatment regimen is superior to chemotherapy without FISH testing, which provided a lower QALY
improvement.is Another limitation to the implementation of
more frequent genetic testing is the lack of pharmaceutical
studies currently conducted on the effects of genetic variation on drug metabolism and overall effect. This kind of research would allow for the research and development of
more targeted medications and could also potentially decrease the frequency of adverse events and toxicity by ensuring chemotherapeutics or other drug agents are only used
within populations which will see benefits outweighing the
risks associated with the drug treatment course.
Conclusion
The benefits of pharmacogenomics have already been observed in chemotherapy through the cases of cetuximab and
trastuzumab. Both agents have demonstrated effectiveness
in oncology patients possessing specific genetic biomarker
characteristics. Cetuximab has been shown to improve outcomes in metastatic colorectal cancers as well as head and
neck squamous cell carcinomas positive for EGFR. Trastuzumab has shown benefit in HER2 overexpressing cancers affecting the breast tissue and gastrointestinal tract. Utilizing
genetic testing is essential for appropriate use of these drugs.
Personalized treatments can greatly improve chances of survival through earlier administration of effective drug therapy
and decreased exposure to toxic antineoplastic agents
unlikely to provide benefit to the patient.16 Developing clinical pharmacy services in pharmacogenomics is one possible
step in implementing the routine use of personalized drug
July 2012 Volume 3, Issue 2
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therapy. Pharmacy services could include providing guidelines to physicians regarding genetic testing, initial drug
selection and dosage adjustments.17 Although pharmacogenomics is still in the early stages in practice, pharmacists can
play a vital role in the implementation and use of pharmacogenomics in therapeutic decision making.
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